Fuelling expansion into new markets
eligibility checklist


Get in touch to make an enquiry about The North West Fund. 

Read more
eligibility checklist


Visit our business support page for useful links to other local, regional and national support organisations.

Read more

Soaring global demand for ChargePoint valves

Fund: Mezzanine

ChargePoint Technology, a Liverpool-based specialist manufacturer for the Pharmaceutical and Biotech sectors has moved to a new multi-million pound production facility amid soaring global demand for its products...

The company supplies precision containment valves to some of the biggest pharmaceutical names across the globe.

The decision to relocate to larger premises in Speke, was made to help the company expand and compete more effectively in the growing aseptic bio-pharma market.

ChargePoint is currently the second largest manufacturer in the world for containment valves and is investing heavily in product development to become the major player for the technology, which is used for transferring raw materials safely and efficiently.

ChargePoint's new headquarters are a 27,000 sq ft production and office space and have been fitted out with more than £1 million worth of technology for the manufacture of the devices that are transforming the way medicines and vaccines are processed.

Managing Director, Chris Eccles said, "Our move is in line with our growth and our ambition and drive to offer the highest quality products for sectors that need to use contained transfers.

"We have invested in state-of-the art technology to improve our unique and progressive devices and this commitment will be evident in the technology in development at present.

"The first quarter of 2016 showed phenomenal growth for the company and we have adapted to the demand around the world for our products."

The company received a £900,000 investment from The North West Fund in 2013 and has used the finance to create more than 65 skilled jobs, as well as expand into new markets.

ChargePoint exports approximately 80% of its products and won the Queen's Award for International Trade in 2012. In 2015, global sales saw a 20% increase on 2014 at just over £8 million.

ChargePoint generates 20% of its annual revenues in the US and its customers include pharma heavyweights such as Merck, Roche Genentech, Johnson & Johnson, Ritedose and Pfizer. It is also seeing rapid growth in countries such as China and India.

Originally developed in 1996 in conjunction with GlaxoSmithKline, ChargePoint valves are now used by almost every major pharmaceutical manufacturer globally and increasingly in other industries such as chemical, food manufacture and consumer goods.


Back to article list